Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Stuart Roger Lipsitz, Sc.D.

Co-Author

This page shows the publications co-authored by Stuart Lipsitz and Quoc-Dien Trinh.
Connection Strength

12.276
  1. Using Cox regression to develop linear rank tests with zero-inflated clustered data. J R Stat Soc Ser C Appl Stat. 2020 Apr; 69(2):393-411.
    View in: PubMed
    Score: 0.857
  2. Racial differences in the treatment and outcomes for prostate cancer in Massachusetts. Cancer. 2021 08 01; 127(15):2714-2723.
    View in: PubMed
    Score: 0.234
  3. Effect of Medicaid Expansion on Receipt of Definitive Treatment and Time to Treatment Initiation by Racial and Ethnic Minorities and at Minority-Serving Hospitals: A Patient-Level and Facility-Level Analysis of Breast, Colon, Lung, and Prostate Cancer. JCO Oncol Pract. 2021 05; 17(5):e654-e665.
    View in: PubMed
    Score: 0.234
  4. Where Is the Value in Ambulatory Versus Inpatient Surgery? Ann Surg. 2021 05 01; 273(5):909-916.
    View in: PubMed
    Score: 0.234
  5. Is Medicaid expansion associated with increases in palliative treatments for metastatic cancer? J Comp Eff Res. 2021 06; 10(9):733-741.
    View in: PubMed
    Score: 0.233
  6. Reply by Authors. J Urol. 2021 05; 205(5):1274.
    View in: PubMed
    Score: 0.231
  7. Cancer Screening Tests and Cancer Diagnoses During the COVID-19 Pandemic. JAMA Oncol. 2021 03 01; 7(3):458-460.
    View in: PubMed
    Score: 0.231
  8. Systematic Review of Time to Definitive Treatment for Intermediate Risk and High Risk Prostate Cancer: Are Delays Associated with Worse Outcomes? J Urol. 2021 May; 205(5):1263-1274.
    View in: PubMed
    Score: 0.229
  9. Inequity in selective referral to high-volume hospitals for genitourinary malignancies. Urol Oncol. 2020 06; 38(6):582-589.
    View in: PubMed
    Score: 0.216
  10. Geographic Distribution of Racial Differences in Prostate Cancer Mortality. JAMA Netw Open. 2020 03 02; 3(3):e201839.
    View in: PubMed
    Score: 0.215
  11. Facility-Level Variation in Pelvic Lymphadenectomy During Radical Prostatectomy and Effect on Overall Survival in Men with High-Risk Prostate Cancer. Ann Surg Oncol. 2020 Jun; 27(6):1929-1936.
    View in: PubMed
    Score: 0.212
  12. Risk of dementia following androgen deprivation therapy for treatment of prostate cancer. Prostate Cancer Prostatic Dis. 2020 09; 23(3):410-418.
    View in: PubMed
    Score: 0.212
  13. Adoption of immunotherapy in the community for patients diagnosed with metastatic melanoma. J Immunother Cancer. 2019 11 07; 7(1):289.
    View in: PubMed
    Score: 0.211
  14. Comparing the Association Between Insurance and Mortality in Ovarian, Pancreatic, Lung, Colorectal, Prostate, and Breast Cancers. J Natl Compr Canc Netw. 2019 09 01; 17(9):1049-1058.
    View in: PubMed
    Score: 0.208
  15. Variation in Positive Surgical Margin Status After Radical Prostatectomy for pT2 Prostate Cancer. Clin Genitourin Cancer. 2019 10; 17(5):e1060-e1068.
    View in: PubMed
    Score: 0.205
  16. Sex-specific Differences in the Quality of Treatment of Muscle-invasive Bladder Cancer Do Not Explain the Overall Survival Discrepancy. Eur Urol Focus. 2021 01; 7(1):124-131.
    View in: PubMed
    Score: 0.205
  17. Comparison of Hospital Readmission After Total Hip and Total Knee Arthroplasty vs Spinal Surgery After Implementation of the Hospital Readmissions Reduction Program. JAMA Netw Open. 2019 05 03; 2(5):e194634.
    View in: PubMed
    Score: 0.203
  18. The current landscape of low-value care in men diagnosed with prostate cancer: what is the role of individual hospitals? Urol Oncol. 2019 09; 37(9):575.e9-575.e18.
    View in: PubMed
    Score: 0.203
  19. Recommended Cancer Screening in Accountable Care Organizations: Trends in Colonoscopy and Mammography in the Medicare Shared Savings Program. J Oncol Pract. 2019 06; 15(6):e547-e559.
    View in: PubMed
    Score: 0.203
  20. Facility Level Variation in Rates of Definitive Therapy for Low Risk Prostate Cancer in Men with Limited Life Expectancy: An Opportunity for Value Based Care Redesign. J Urol. 2019 04; 201(4):728-734.
    View in: PubMed
    Score: 0.202
  21. Quality of Care in the Treatment of Localized Intermediate and High Risk Prostate Cancer at Minority Serving Hospitals. J Urol. 2019 04; 201(4):735-741.
    View in: PubMed
    Score: 0.202
  22. Association of Care at Minority-Serving vs Non-Minority-Serving Hospitals With Use of Palliative Care Among Racial/Ethnic Minorities With Metastatic Cancer in the United States. JAMA Netw Open. 2019 02 01; 2(2):e187633.
    View in: PubMed
    Score: 0.200
  23. Comparing Long-Term Outcomes Following Radical and Partial Nephrectomy for cT1 Renal Cell Carcinoma in Young and Healthy Individuals. JNCI Cancer Spectr. 2019 Mar; 3(1):pkz003.
    View in: PubMed
    Score: 0.200
  24. Contemporary Survival Rates for Muscle-Invasive Bladder Cancer Treated With Definitive or Non-Definitive Therapy. Clin Genitourin Cancer. 2019 06; 17(3):e488-e493.
    View in: PubMed
    Score: 0.200
  25. Impact of tumor, treatment, and access on outcomes in bladder cancer: Can equal access overcome race-based differences in survival? Cancer. 2019 04 15; 125(8):1319-1329.
    View in: PubMed
    Score: 0.199
  26. Comparison of testis cancer-specific survival: an analysis of national cancer registry data from the USA, UK and Germany. BJU Int. 2019 03; 123(3):385-387.
    View in: PubMed
    Score: 0.198
  27. Neoadjuvant Androgen Deprivation Therapy Prior to Radical Prostatectomy: Recent Trends in Utilization and Association with Postoperative Surgical Margin Status. Ann Surg Oncol. 2019 Jan; 26(1):297-305.
    View in: PubMed
    Score: 0.197
  28. Comparative Effectiveness of Radical Prostatectomy Versus External Beam Radiation Therapy Plus Brachytherapy in Patients with High-risk Localized Prostate Cancer. Eur Urol. 2019 04; 75(4):552-555.
    View in: PubMed
    Score: 0.197
  29. Use of Preventive Health Services Among Cancer Survivors in the U.S. Am J Prev Med. 2018 12; 55(6):830-838.
    View in: PubMed
    Score: 0.196
  30. Multilevel Analysis of Readmissions After Radical Cystectomy for Bladder Cancer in the USA: Does the Hospital Make a Difference? Eur Urol Oncol. 2019 07; 2(4):349-354.
    View in: PubMed
    Score: 0.195
  31. Investigating the effect of treatment at high-volume hospitals on overall survival following cytoreductive nephrectomy. Urol Oncol. 2018 09; 36(9):400.e15-400.e22.
    View in: PubMed
    Score: 0.194
  32. Evaluation of the contribution of demographics, access to health care, treatment, and tumor characteristics to racial differences in survival of advanced prostate cancer. Prostate Cancer Prostatic Dis. 2019 03; 22(1):125-136.
    View in: PubMed
    Score: 0.194
  33. Liver Disease in Men Undergoing Androgen Deprivation Therapy for Prostate Cancer. J Urol. 2018 09; 200(3):573-581.
    View in: PubMed
    Score: 0.189
  34. Impact of testosterone replacement therapy on thromboembolism, heart disease and obstructive sleep apnoea in men. BJU Int. 2018 05; 121(5):811-818.
    View in: PubMed
    Score: 0.187
  35. The effect of treatment at minority-serving hospitals on outcomes for bladder cancer. Urol Oncol. 2018 05; 36(5):238.e7-238.e17.
    View in: PubMed
    Score: 0.187
  36. Reassessing the value of high-volume cancer care in the era of precision medicine. Cancer. 2018 04 01; 124(7):1319-1321.
    View in: PubMed
    Score: 0.187
  37. Adjuvant Chemotherapy vs Observation for Patients With Adverse Pathologic Features at Radical Cystectomy Previously Treated With Neoadjuvant Chemotherapy. JAMA Oncol. 2018 Feb 01; 4(2):225-229.
    View in: PubMed
    Score: 0.187
  38. Comparative effectiveness of robot-assisted vs. open radical cystectomy. Urol Oncol. 2018 03; 36(3):88.e1-88.e9.
    View in: PubMed
    Score: 0.185
  39. Impact of adequate pelvic lymph node dissection on overall survival after radical cystectomy: A stratified analysis by clinical stage and receipt of neoadjuvant chemotherapy. Urol Oncol. 2018 02; 36(2):78.e13-78.e19.
    View in: PubMed
    Score: 0.184
  40. Variation in the use of active surveillance for low-risk prostate cancer. Cancer. 2018 Jan 01; 124(1):55-64.
    View in: PubMed
    Score: 0.182
  41. Effect of Nonurothelial Histologic Variants on the Outcomes of Radical Cystectomy for Nonmetastatic Muscle-invasive Urinary Bladder Cancer. Clin Genitourin Cancer. 2017 Aug 24.
    View in: PubMed
    Score: 0.181
  42. The Use of Prostate Specific Antigen Screening in Purchased versus Direct Care Settings: Data from the TRICAREĀ® Military Database. J Urol. 2017 12; 198(6):1295-1300.
    View in: PubMed
    Score: 0.179
  43. Morbidity and Mortality of Locally Advanced Prostate Cancer: A Population Based Analysis Comparing Radical Prostatectomy versus External Beam Radiation. J Urol. 2017 11; 198(5):1061-1068.
    View in: PubMed
    Score: 0.178
  44. Accountable care organizations and the use of cancer screening. Prev Med. 2017 Aug; 101:15-17.
    View in: PubMed
    Score: 0.178
  45. Comparative Effectiveness of Trimodal Therapy Versus Radical Cystectomy for Localized Muscle-invasive Urothelial Carcinoma of the Bladder. Eur Urol. 2017 10; 72(4):483-487.
    View in: PubMed
    Score: 0.176
  46. Efficient Computation of Reduced Regression Models. Am Stat. 2017; 71(2):171-176.
    View in: PubMed
    Score: 0.175
  47. The association of hypoalbuminemia with early perioperative outcomes - A comprehensive assessment across 16 major procedures. Am J Surg. 2017 Nov; 214(5):871-883.
    View in: PubMed
    Score: 0.172
  48. Efficacy of High-Intensity Local Treatment for Metastatic Urothelial Carcinoma of the Bladder: A Propensity Score-Weighted Analysis From the National Cancer Data Base. J Clin Oncol. 2016 10 10; 34(29):3529-3536.
    View in: PubMed
    Score: 0.170
  49. Determinants of cancer screening in Asian-Americans. Cancer Causes Control. 2016 08; 27(8):989-98.
    View in: PubMed
    Score: 0.167
  50. The influence of marital status on the use of breast, cervical, and colorectal cancer screening. Prev Med. 2016 08; 89:140-145.
    View in: PubMed
    Score: 0.166
  51. Surgeon and Hospital Level Variation in the Costs of Robot-Assisted Radical Prostatectomy. J Urol. 2016 Oct; 196(4):1090-5.
    View in: PubMed
    Score: 0.165
  52. Data on Medicare eligibility and cancer screening utilization. Data Brief. 2016 Jun; 7:679-81.
    View in: PubMed
    Score: 0.163
  53. The impact of Medicare eligibility on cancer screening behaviors. Prev Med. 2016 Apr; 85:47-52.
    View in: PubMed
    Score: 0.161
  54. Racial Differences in the Surgical Care of Medicare Beneficiaries With Localized Prostate Cancer. JAMA Oncol. 2016 Jan; 2(1):85-93.
    View in: PubMed
    Score: 0.161
  55. Population-based assessment of prostate-specific antigen testing for prostate cancer in the elderly. Urol Oncol. 2015 Feb; 33(2):69.e29-34.
    View in: PubMed
    Score: 0.146
  56. Recovery of cancer screening tests and possible associated disparities after the first peak of the COVID-19 pandemic. Cancer Cell. 2021 08 09; 39(8):1042-1044.
    View in: PubMed
    Score: 0.059
  57. Impact of high-intensity local treatment on overall survival in stage IV upper tract urothelial carcinoma. Urol Oncol. 2021 07; 39(7):436.e1-436.e10.
    View in: PubMed
    Score: 0.058
  58. Racial Disparities in Treatment for Rectal Cancer at Minority-Serving Hospitals. J Gastrointest Surg. 2021 07; 25(7):1847-1856.
    View in: PubMed
    Score: 0.055
  59. Delayed nephrectomy has comparable long-term overall survival to immediate nephrectomy for cT1a renal cell carcinoma: A population-based analysis. Urol Oncol. 2020 03; 38(3):74.e13-74.e20.
    View in: PubMed
    Score: 0.053
  60. Development and Validation of a Bedside Risk Assessment for Sustained Prescription Opioid Use After Surgery. JAMA Netw Open. 2019 07 03; 2(7):e196673.
    View in: PubMed
    Score: 0.051
  61. Contemporary national trends in prostate cancer risk profile at diagnosis. Prostate Cancer Prostatic Dis. 2020 03; 23(1):81-87.
    View in: PubMed
    Score: 0.051
  62. Impact of adjuvant chemotherapy in patients with adverse features and variant histology at radical cystectomy for muscle-invasive carcinoma of the bladder: Does histologic subtype matter? Cancer. 2019 05 01; 125(9):1449-1458.
    View in: PubMed
    Score: 0.050
  63. Effect of Medicaid Expansion on Colorectal Cancer Screening Rates. Dis Colon Rectum. 2019 01; 62(1):97-103.
    View in: PubMed
    Score: 0.050
  64. Contemporary perceptions of human papillomavirus and penile cancer: Perspectives from a national survey. Can Urol Assoc J. 2019 Feb; 13(2):32-37.
    View in: PubMed
    Score: 0.048
  65. Effectiveness of Neoadjuvant Chemotherapy for Muscle-invasive Bladder Cancer in the Current Real World Setting in the USA. Eur Urol Oncol. 2018 05; 1(1):83-90.
    View in: PubMed
    Score: 0.048
  66. Associations of specific postoperative complications with costs after radical cystectomy. BJU Int. 2018 03; 121(3):428-436.
    View in: PubMed
    Score: 0.046
  67. Racial Disparity in Delivering Definitive Therapy for Intermediate/High-risk Localized Prostate Cancer: The Impact of Facility Features and Socioeconomic Characteristics. Eur Urol. 2018 Mar; 73(3):445-451.
    View in: PubMed
    Score: 0.045
  68. Effectiveness of Adjuvant Chemotherapy After Radical Nephroureterectomy for Locally Advanced and/or Positive Regional Lymph Node Upper Tract Urothelial Carcinoma. J Clin Oncol. 2017 Mar 10; 35(8):852-860.
    View in: PubMed
    Score: 0.043
  69. Population-based comparative effectiveness of salvage radical prostatectomy vs cryotherapy. Urology. 2014 Mar; 83(3):653-7.
    View in: PubMed
    Score: 0.036
  70. Propensity-matched comparison of morbidity and costs of open and robot-assisted radical cystectomies: a contemporary population-based analysis in the United States. Eur Urol. 2014 Sep; 66(3):569-76.
    View in: PubMed
    Score: 0.035
  71. Population-based determinants of radical prostatectomy operative time. BJU Int. 2014 May; 113(5b):E112-8.
    View in: PubMed
    Score: 0.035
  72. Optimal timing of early versus delayed adjuvant radiotherapy following radical prostatectomy for locally advanced prostate cancer. Urol Oncol. 2014 Apr; 32(3):303-8.
    View in: PubMed
    Score: 0.035
  73. Use of surveillance imaging following treatment of small renal masses. J Urol. 2013 Nov; 190(5):1680-5.
    View in: PubMed
    Score: 0.034
  74. Patterns of care and outcomes of radiotherapy for lymph node positivity after radical prostatectomy. BJU Int. 2013 Jun; 111(8):1208-14.
    View in: PubMed
    Score: 0.033
  75. Comparative effectiveness, costs and trends in treatment of small renal masses from 2005 to 2007. BJU Int. 2013 Aug; 112(4):E273-80.
    View in: PubMed
    Score: 0.033
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.